Results 51 to 60 of about 1,097,723 (197)

Trafficking and signalling of oncogenic met [PDF]

, 2010
PhDThe Receptor Tyrosine Kinase (RTK) Met influences behaviour of several cancers by controlling growth, survival and metastasis. Recently, compartmentalisation of signals generated by RTKs, due to their endocytosis / trafficking, has emerged as a ...
Joffre, Carine
core   +2 more sources

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients

Acta Dermato-Venereologica
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation.
Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo   +5 more
doaj   +1 more source

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Frontiers in Pharmacology, 2020
Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa, Ivan Alvarez-Twose   +1 more
doaj   +1 more source

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase. [PDF]

PLoS ONE, 2015
The c-abl proto-oncogene encodes a nonreceptor tyrosine kinase that is found in all metazoans, and is ubiquitously expressed in mammalian tissues. The Abl tyrosine kinase plays important roles in the regulation of mammalian cell physiology.
Saadat U Aleem, Barbara P Craddock, W Todd Miller   +2 more
doaj   +1 more source

Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn

Journal of Alzheimer’s Disease, 2018
The protein tyrosine kinase Pyk2 is encoded by PTK2B, a novel Alzheimer’s disease (AD) susceptibility variant, with the PTK2B risk allele being associated with increased mRNA levels, suggestive of increased Pyk2 levels. However, the role of Pyk2, a member of the focal adhesion kinase (FAK) family, in AD pathology and its regulation are largely unknown.
Li, Chuanzhou, Götz, Jürgen
openaire   +6 more sources

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

Haematologica, 2011
Background Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia.
Benjamin Hanfstein, Martin C. Müller, Sebastian Kreil, Thomas Ernst, Thomas Schenk, Christian Lorentz, Uwe Schwindel, Armin Leitner, Rüdiger Hehlmann, Andreas Hochhaus   +9 more
doaj   +1 more source

Molecular networks in FGF signaling: Flotillin-1 and Cbl-associated protein compete for the binding to fibroblast growth factor receptor substrate 2 [PDF]

, 2012
Fibroblast growth factor receptor substrate 2 (FRS2α) is a signaling adaptor protein that regulates downstream signaling of many receptor tyrosine kinases.
Traub Stephanie, Tomasovic, Ana, Stephanie Traub, Ana Tomasovic, Ana Tomasovic (189773), Ritva Tikkanen (189783), Tikkanen Ritva, Tikkanen, Ritva, Traub, Stephanie, Tomasovic Ana, Ritva Tikkanen, Stephanie Traub (189777)   +11 more
core   +2 more sources

Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase [PDF]

, 2009
Proline-rich tyrosine kinase 2 (PYK2) can be activated by angiotensin II (Ang II) and reactive oxygen species. We report that in endothelial cells, Ang II enhances the tyrosine phosphorylation of endothelial NO synthase (eNOS) in an AT1-, H2O2-, and PYK2-
Loot, Annemarieke E., Ingrid Fleming, Annemarieke E. Loot, Fißlthaler, Beate, Fleming, Ingrid, Judith G. Schreiber, Beate Fisslthaler, Schreiber, Judith G.   +7 more
core   +1 more source

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

Revista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moises M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles   +8 more
doaj   +1 more source